Copy Link Print Information

Osimertinib dimesylate

(Synonyms: AZD-9291 dimesylate; Mereletinib dimesylate)
202 Cited Publications
고객리뷰

Based on 202 publication(s) in Google Scholar

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity: 99.00%
  • CAS No.: 2070014-82-1
  • 화학식: C30H41N7O8S2
  • 분자량:691.82
  • 보관:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Osimertinib dimesylate Chemical Structure
    Osimertinib dimesylate Chemical Structure
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
  • Experimental Validation Results for Osimertinib dimesylate
CAS No.: 2070014-82-1
사이즈
가격
재고
수량
Amount: USD 0.00
Please select quantity
or
or

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Osimertinib dimesylate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
주변의 대리점 찾기 Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • 용액&용해도
  • Protocol
  • 순도&문서
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Osimertinib dimesylate

More
Customer Validation & Images
IFBio/Physico-chemical AssayFlow CytometryWBIn Vivo Efficacy StudyCell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • IF
  • In Vivo Efficacy Study
  • WB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • IF
  • Bio/Physico-chemical Assay
  • WB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • WB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • IF
  • IF
  • WB
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All EGFR Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress 로그인
Register
Sign in to MedChemExpress
회원가입

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Osimertinib dimesylate Chemical Structure
    Osimertinib dimesylate Chemical Structure
    1/16
  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Science. 2026 Mar 26;391(6792):eadz9353. [Abstract]

    Customer Validation
     Cell viability of PC9 cells treated with the indicated concentrations of Osimertinib (4 days). (n = 3 independent culture replicates). Red arrow represents concentration used for subsequent experiments.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Science. 2026 Mar 26;391(6792):eadz9353. [Abstract]

    Customer Validation
     Representative immunofluorescence images of PC9 cells stained for PI3 (green), FN1 (red), and nuclei [4′,6-diamidino-2-phenylindole (DAPI), blue] with or without 100 nM Osimertinib (4 days) treatment (scale bar, 50 μm).

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 May:86:101379. [Abstract]

    Customer Validation
     Photographs of Osimertinib-resistant mouse models and tumors on the 28th day (n = 5 per group). Nude mice were subcutaneously injected with Osimertinib-resistant PC-9 cells. When the tumors were formed, the mice were intratumorally injected with sh-NC/sh-STAB1 macrophages, and treated with vehicle or 5 mg/kg Osimertinib by oral gavage once daily for 28 days.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Feb 24;17(1):3113. [Abstract]

    Customer Validation
     Western blot analysis of IBI334 and Osimertinib in NCI-H1975LTC cells (n = 2 biological replicates). For Western blot analysis, cells were treated with 50 nM Osimertinib and/or 100 nM IBI334 for 4 h.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 Jun:93:104172. [Abstract]

    Customer Validation
     Cell viability following 48 h treatment with Osimertinib (1 μM) was measured using MTT assays.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]

    Customer Validation
     Cells were treated for 72 h with the indicated concentrations of compounds (Osimertinib, etc.), and cell viability wasdetermined. Synergy scores (ZIP values) were calculated using the Zero Interaction Potency (ZIP)model in SynergyFinder (n = 3).

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]

    Customer Validation
     Cells were treated for 72 h with the indicated concentrations of compounds (Osimertinib, etc.), and cell viability wasdetermined. Synergy scores (ZIP values) were calculated using the Zero Interaction Potency (ZIP)model in SynergyFinder (n = 3).

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]

    Customer Validation
     Cells were treated for 72 h with the indicated concentrations of compounds (Osimertinib, etc.), and cell viability wasdetermined. Synergy scores (ZIP values) were calculated using the Zero Interaction Potency (ZIP)model in SynergyFinder (n = 3).

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]

    Customer Validation
     Cells were treated for 72 h with the indicated concentrations of compounds (Osimertinib, etc.), and cell viability wasdetermined. Synergy scores (ZIP values) were calculated using the Zero Interaction Potency (ZIP)model in SynergyFinder (n = 3).

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Eur Heart J. 2025 Dec 3:ehaf813. [Abstract]

    Customer Validation
     There was marked sarcomere disarray with evidence of sarcomere fragmentation and aggregation upon 7-day treatment of Osimertinib (0.1-1 μM) in induced pluripotent stem cell-derived cardiomyocytes.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Eur Heart J. 2025 Dec 3:ehaf813. [Abstract]

    Customer Validation
     Osimertinib treatment (0.01–10 µM; 7 days) led to dose-dependent reduction in systolic (area under the curve, peak height, and departure velocity) measures in induced pluripotent stem cell-derived cardiomyocytes. n = 12 per group.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Eur Heart J. 2025 Dec 3:ehaf813. [Abstract]

    Customer Validation
     There was a significant decrease in the protein level of MYLK3 following 7-day treatment of Osimertinib (1 µM). Additionally, MYL2 phosphorylation was also significantly reduced.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Eur Heart J. 2025 Dec 3:ehaf813. [Abstract]

    Customer Validation
     Eight-week-old wild-type mice were subjected to transverse aortic constriction. After 1 week, Osimertinib (Osi, 25 mg/kg; oral gavage; once daily)-only treatment was conducted in Group 1, and Osimertinib and omecamtiv co-treatment was performed in Group 2. After another 2 weeks, omecamtiv treatment was initiated for the Osimertinib-only mice (Group 1). Echocardiography was conducted every week. Omecamtiv co-treatment effectively prevented left ventricular contractile dysfunction by Osimertinib in the course of 2 weeks, as revealed by an increase of ejection fraction and fractional shortening. When Osimertinib-treated mice with apparent cardiac dysfunction were introduced to omecamtiv co-treatment later, there was restoration of left ventricular contractile function.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Aug;37(32):e2504050. [Abstract]

    Customer Validation
     The cell viability of Osimertinib -resistant H1975OE cells pre-treated without (Control) or with 500 nM AP-CRTACEGFR for 6 h, followed by 48 h of exposure to various concentrations of Osimertinib (Osi). The results of cell viability assay demonstrated that H1975OE cells exhibited resistance to Osimertinib, but AP-CRTACEGFR increased the sensitivity of H1975OE cells to Osimertinib.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Aug;37(32):e2504050. [Abstract]

    Customer Validation
     The phosphorylation levels of EGFR-downstream substrates in H1975OE cells treated without (Control) or with 500 nM AP-CRTACEGFR for 24 h, followed by 6 h of exposure to various concentrations of Osimertinib (Osi). The results showed that AP-CRTACEGFR effectively enhanced the efficacy of Osimertinib in inhibiting the phosphorylation of downstream signaling proteins.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Aug;37(32):e2504050. [Abstract]

    Customer Validation
     Osimertinib (5 mg/kg; i.g.; once every two days for 14 days) monotherapy did not markedly inhibit tumor growth or reduce tumor weight in patient‑derived xenograft (PDX) mice, whereas combination treatment with AP-CRTACEGFR (80 nM/kg; i.t.; once every two days for 14 days) plus Osimertinib significantly suppressed tumor growth and decreased tumor weight.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Feb 1;85(3):585-601. [Abstract]

    Customer Validation
     T-cell–mediated tumor cell killing assay of LLC co-mutant cell models treated with Osimertinib (1 μmol/L) or αPD-1 antibody alone or in combination (5 μg/mL). The tumor cells were cocultured with activated T cells for 72 hours. The remaining viable cells were stained with crystal violet. The results showed, compared with single treatment, Egfr/Trp53 and Egfr/Cdkn2a cells showed more sensitivity to the combination treatment of EGFR-TKI (Osimertinib) and PD-1 mAb.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Feb 1;85(3):585-601. [Abstract]

    Customer Validation
     T-cell–mediated tumor cell killing assay of LLC-Em cells. Cells were treated with or without anti–PD-L2 antibody, were given Osimertinib (1 μmol/L), selumetinib (1 μmol/L), and Osimertinib + selumetinib, respectively, and then cocultured with activated T cells for 72 hours. IFNγ secreted by CD8+ T cells was analyzed by flow cytometry.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Feb 1;85(3):585-601. [Abstract]

    Customer Validation
     Tumor-bearing mice were treated with saline, Osimertinib (10 mg/kg), and ZU (100 mg/kg) intragastrically 5 times per week. Mouse anti-CD8 antibody was administered for four consecutive days on days 5 and 12 at 200 μg per mouse via i.p. injection. The models were divided into solvent groups, Osimertinib groups, small-molecule inhibitors ZU, and Osimertinib ZU combined administration groups, and ZU combined administration accompanied CD8+ T-cell depletion. Curves showing the tumor volumes from mice in the different groups (n = 6). The results showed that compared with the control treatment, combined Osimertinib and ZU administration significantly inhibited the growth of ectopic tumors, with the inhibition rate reaching 84.9%, but the antitumor effect of the combined treatment was obviously reduced when a CD8 blocking antibody was present.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Mar 21:S1097-2765(25)00194-7. [Abstract]

    Customer Validation
     PC9 cell proliferation assay in 100 nM Osimertinib for the indicated conditions, normalized to treatment day 1. n=2 biological replicates. The results showed that PC9 cells expressing NKX2-1 exhibited a reduced maximum killing at day 10 with Osimertinib treatment, and cells specifically increased proliferation by day 17.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

    Customer Validation
     HCC827 (EGFR mutant) and NCI-H2228 (ALK-translocated) lung cancer cells were treated with 100 nM of the EGFR inhibitor Osimertinib or 500 nM of the ALK inhibitor alectinib for 72 h, respectively. Representative immunofluorescence images of E-cadherin were merged with DAPI. Scale bar, 10 μm.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

    Customer Validation
     HCC827 and NCI-H2228 cancer cell lines were treated with 100 nM Osimertinib, 500 nM alectinib or 50 nM trametinib for 72 h as indicated. Immunofluorescence images of Scrib were merged with DAPI. Scale bar, 10 μm.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

    Customer Validation
     Osimertinib-induced MRAS activation was abrogated by the addition of either SHP2 or SOS1 inhibitor in HCC827 cells. HCC827 cells were treated with 100 nM Osimertinib with or without 10 μM BI-3406 or 10 μM SHP099 for 72 h.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]

    Customer Validation
     Measurement of antiproliferation effects of AZD9291 (Osimertinib) (0.5-2 μM; 24 h) by EdU incorporation assay.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]

    Customer Validation
     U87 and U251 cells are exposed to indicated concentrations of AZD9291 (Osimertinib) for 24 h and then stimulated with EGF (100 ng/mL) for 30 min. Cell lysates are prepared and examined using Western blot analysis with indicated antibodies.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]

    Customer Validation
     U87 and U251 cells are treated with AZD9291 (Osimertinib) or CP-358774 for 4, 24 and 48 h. The expression level of p-ERK are assessed using Western blot analysis.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]

    Customer Validation
     GBM cells were treated by different concentrations of AZD9291 (Osimertinib) (0.625–20 μM) for 72 h. The cell viability was examined by CCK8 assay. Comparation of different sensitive of GBM cells to EGFR inhibitors (AZD9291, Erlotinib and Gefitinib).

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 Dec;40(12):1587-1595. [Abstract]

    Customer Validation
     MDAMB-453 cells are pre-treated with 10 μM MG132 for 1 h before treatment with the 20 μM AZD for 4 h. Cell lysates were used for SDS PAGE and Western blotting. AZD9291 disrupts the EZH2–EED interaction by binding to EZH2 directly

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2019 Apr;34(4):476-485. [Abstract]

    Customer Validation
     Protein levels of p-EGFR(Tyr1068), p-EGFR(Tyr1137), EGFR, p-STAT3, STAT3, p-AKT, AKT, p-p38 MAPK, and p-ERK MAPK are analyzed in GST-Der pII1-129-stimulated human epithelial cells with/without AZD-9291 (Osimertinib) treatment.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2019 Apr;34(4):476-485. [Abstract]

    Customer Validation
     Protein levels of p-EGFR(Tyr1068), p-EGFR(Tyr1137), EGFR, p-STAT3, STAT3, p-AKT, AKT, p-p38 MAPK, and p-ERK MAPK are analyzed in GST-Der pII1-129-stimulated human epithelial cells with/without AZD-9291 (Osimertinib) treatment.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2019 Apr;34(4):476-485. [Abstract]

    Customer Validation
     Protein levels of NF-κB and IκB are analyzed are analyzed in GST-Der pII1-129-stimulated human epithelial cells with/without AZD-9291 (Osimertinib) treatment.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4. [Abstract]

    Customer Validation
     Negligible increases in caspase-3 activity or PARP-1 cleavage is observed in H1975 NSCLC cells treated with DMSO, single agent PAC-1 (5 mM), or Osimertinib (Osi). In cells treated with PAC-1+Osimertinib, dramatic increases in caspase-3 activity is observed as early as 36 hr post treatment.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Mar 14;8(11):18359-18372. [Abstract]

    Customer Validation
     In all of the cell lines tested, AZD9291 (Osimertinib) significantly affects the phosphorylation of eIF4E, which presumably is due to its strong inhibitory activity against MNK2 kinase.

  • 1/16

    Osimertinib dimesylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Mar 14;8(11):18359-18372. [Abstract]

    Customer Validation
     In all of the cell lines tested, AZD9291 (Osimertinib) significantly affects the phosphorylation of eIF4E, which presumably is due to its strong inhibitory activity against MNK2 kinase.

  • Osimertinib dimesylate